ArticleCurrent medical science2026
A 3D PDMS Scaffold Microchip Platform for Non-Invasive Detection of Circulating Endometrial Cells: Revolutionizing Endometriosis Diagnosis.
Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo address the urgent need for non-invasive diagnosis of endometriosis, this study developed a novel microfluidic platform utilizing a three-dimensional (3D) polydimethylsiloxane scaffold microchip to efficiently capture circulating endometrial cells (CECs).
methodsA prospective single-center study was performed from June 2022 to June 2023. Presurgical peripheral blood was collected from 42 patients with endometriosis and 20 controls. Microchips were functionalized with antibodies against epithelial cellular adhesion molecule (EpCAM) and cluster of differentiation 10 (CD10). They were used to capture and identify CECs for diagnostic evaluation.
resultsThe presence of CD10 was observed in 88.10% of cases (37/42), significantly higher than in controls (35%, 7/20, P < 0.001). Similarly, the levels of EpCAM were detected in 52.38% of cases (22/42) and 30% of controls (6/20, P = 0.25). In preoperative diagnosis, integrating CECs with clinical parameters achieved superior accuracy (AUC = 0.870) compared to CA125 (AUC = 0.813) and clinical-only models (AUC = 0.606-0.923). When comparing CEC levels before and after surgery, the CEC-integrated clinical model demonstrated robust diagnostic performance (AUC = 0.877).
conclusionThis 3D microfluidic platform enables precise, convenient, and non-invasive endometriosis identification via efficient CEC capture, offering significant potential for clinical translation.
Indexed as
Identifiers
42530785What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.